Effects of dopamine on reinforcement learning in Parkinson&apos;s disease depend on motor phenotype

Parkinson’s Disease

Dopamine effects on frontal cortical blood flow and motor inhibition in Parkinson's disease

doi: 10.1016/j.cortex.2019.01.016.

Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation

Lancet Neurol.

Latourelle JC, Beste MT, Hadzi TC, Miller RE, Oppenheim JN, Valko MP, Wuest DM, Church BW, Khalil IG, Hayete B, Venuto CS

doi: 10.1016/

Aging and Cognitive FunctionsAnxiety and Depression

The impact of Tai Chi and Qigong mind-body exercises on motor and non-motor function and quality of life in Parkinson's disease: A systematic review and meta-analysis

Parkinsonism Relat Disord.

Song R, Grabowska W, Park M, Osypiuk K, Vergara-Diaz GP, Bonato P, Hausdorff JM, Fox M, Sudarsky LR, Macklin E, Wayne PM

doi: 10.1016/

Anxiety and Depression

Long-Term Effects of Safinamide on Mood Fluctuations in Parkinson's Disease

J Parkinsons Dis.

Cattaneo C, Müller T, Bonizzoni E, Lazzeri G, Kottakis I, Keywood C

doi: 10.3233/JPD-171143.

Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial

Lancet Neurol.

Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, Henriksen T, van Laar T, Spivey K, Vel S, Staines H, Lees A

doi: 10.1016/S1474-

Parkinson’s Disease

Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study

Lancet Neurol.

Wilson H, Dervenoulas G, Pagano G, Koros C, Yousaf T, Picillo M, Polychronis S, Simitsi A, Giordano B, Chappell Z, Corcoran B, Stamelou M, Gunn RN, Pellecchia MT, Rabiner EA, Barone P, Stefanis L, Politis M

doi: 10.1016/S1474-4422

Parkinson’s Disease

Developing and validating Parkinson's disease subtypes and their motor and cognitive progression

J Neurol Neurosurg Psychiatry.

Lawton M, Ben-Shlomo Y, May MT, Baig F, Barber TR, Klein JC, Swallow DMA, Malek N, Grosset KA, Bajaj N, Barker RA, Williams N, Burn DJ, Foltynie T, Morris HR, Wood NW, Grosset DG, Hu MTM

doi: 10.1136/jnnp-2018-318337.

Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Cohort

JAMA Neurol.

Jennings D, Siderowf A, Stern M, Seibyl J, Eberly S, Oakes D, Marek K; PARS Investigators

doi: 10.1001/jamaneurol.

Functional monoamine oxidase B gene intron 13 polymorphism predicts putaminal dopamine turnover in de novo Parkinson's disease

Mov Disord.

Löhle M, Mangone G, Wolz M, Beuthien-Baumann B, Oehme L, van den Hoff J, Kotzerke J, Reichmann H, Corvol JC, Storch A

doi: 10.1002/mds.27466.

Neurology · Psychiatry

Effects of dopamine on reinforcement learning in Parkinson's disease depend on motor phenotype

Related content

Dopamine effects on frontal cortical blood flow and motor inhibition in Parkinson's disease

Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation

The impact of Tai Chi and Qigong mind-body exercises on motor and non-motor function and quality of life in Parkinson's disease: A systematic review and meta-analysis

Long-Term Effects of Safinamide on Mood Fluctuations in Parkinson's Disease

Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial

Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study

Developing and validating Parkinson's disease subtypes and their motor and cognitive progression

Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Cohort

Functional monoamine oxidase B gene intron 13 polymorphism predicts putaminal dopamine turnover in de novo Parkinson's disease